IPP Bureau
Moderna receives U.S. FDA approval for RSV Vaccine mRESVIA
By IPP Bureau - June 01, 2024
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
AbbVie receives positive CHMP opinion for Risankizumab for treatment ulcerative colitis
By IPP Bureau - June 01, 2024
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
BlueRock Therapeutics receives FDA RMAT designation for Parkinson’s disease cell therapy candidate bemdaneprocel
By IPP Bureau - May 31, 2024
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
Merck inks MoU with KAIST to advance scientific collaboration
By IPP Bureau - May 30, 2024
Partnership to facilitate collaborative research in academia and industry to further progress in life sciences
Hyperfine bringing Swoop to India through distribution partnership with Radiosurgery Global
By IPP Bureau - May 30, 2024
Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market
FDA grants priority review to Merck’s application for Keytruda plus chemotherapy for metastatic malignant pleural mesothelioma
By IPP Bureau - May 30, 2024
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
Valent BioSciences opens new addition at Melnik and Shafer Biorational Research Center
By IPP Bureau - May 30, 2024
Greg was also central to the planning, design, and construction of this facility
Merck KGaA to set up € 300 million Bioprocessing Production Center in South Korea
By IPP Bureau - May 30, 2024
The new facility will accelerate the biotech and pharmaceutical industry's development by manufacturing vaccines, cell and gene therapies, and protein-based therapies
Alembic Pharmaceuticals receives USFDA final approval for Sacubitril and Valsartan Tablets
By IPP Bureau - May 30, 2024
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Merck to acquire EyeBio for US$ 1.3 billion upfront payment
By IPP Bureau - May 30, 2024
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Lilly increases manufacturing investment to US$ 9 billion at newest Indiana site
By IPP Bureau - May 29, 2024
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Strides receives USFDA approval for Sucralfate oral suspension, 1gm/10 mL
By IPP Bureau - May 29, 2024
Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation
IGC Pharma announces patient enrollment at Neurostudies in Phase 2 trial investigating IGC-AD1
By IPP Bureau - May 29, 2024
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Asahi Kasei to acquire Calliditas Therapeutics AB to accelerate growth
By IPP Bureau - May 29, 2024
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
